Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an orally bioavailable thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies. References:

纯度：≥98%

CAS：851606-62-7